Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 5/20 | 0.57 |
| ▸ | LMNA | P02545 | 6/20 | 0.56 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.56 |
| ▸ | CDK2 | P24941 | 2/20 | 0.55 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | BRD4 | O60885 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | BRAF | P15056 | 2/20 | 0.53 |
| ▸ | TOP2A | P11388 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.52 |
| ▸ | PI4KA | P42356 | 1/20 | 0.52 |
| ▸ | XDH | P47989 | 1/20 | 0.52 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29420373 | 1.00 | CYP3A4 (0.62) | CYP3A4CYP1A2HIF1AHTTLMNA | |
| SCHEMBL11591794 | 0.82 | HTT (0.59) | CYP3A4CYP1A2HIF1AHTTLMNA | |
| SCHEMBL8652766 | 0.81 | LMNA (0.54) | CYP3A4CYP1A2HIF1AHTTLMNA | |
| SCHEMBL29380490 | 0.80 | HTT (0.62) | CYP3A4CYP1A2HIF1AHTTLMNA | |
| SCHEMBL30374699 | 0.80 | MKNK1 (0.58) | CYP3A4CYP1A2HIF1AHTTLMNA | |
| SCHEMBL17901710 | 0.80 | HTT (0.57) | CYP3A4CYP1A2HIF1AHTTLMNA | |
| SCHEMBL1095418 | 0.80 | CYP1A2 (0.60) | CYP3A4CYP1A2HIF1AHTTLMNA | |
| SCHEMBL9116347 | 0.80 | HTT (0.57) | CYP3A4CYP1A2HIF1AHTTLMNA | |
| SCHEMBL21914 | 0.80 | HTT (0.62) | CYP3A4CYP1A2HIF1AHTTLMNA | |
| SCHEMBL18640374 | 0.79 | CYP3A4 (0.76) | CYP3A4CYP1A2HIF1AHTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1277 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026106497-A2 | FUNCTIONALIZED CIRCULAR RNA AND METHODS AND INTERMEDIATES FOR THEIR PRODUCTION | SIEĆ BADAWCZA ŁUKASIEWICZ – PORT POLSKI OSRODEK ROZWOJU TECHNOLOGII (PL) | 2026-05-21 | — | — | WO | claimed |
| WO-2025024123-A1 | NOVEL CITICOLINE DERIVATIVES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | claimed |
| CN-118931997-A | Method for synthesizing adenosine and/or uridine by three-enzyme cascade catalysis | 上海飞腾医药科技有限公司 | 2024-11-12 | — | — | CN | claimed |
| US-20170183645-A1 | COMPOSITION AND METHOD FOR DIVERSIFYING POLYPEPTIDE LIBRARIES | ABZYME THERAPEUTICS LLC | 2017-06-29 | — | — | US | claimed |
| US-9677067-B2 | Compositions and methods for synthetic gene assembly | Twist Bioscience Corporation (US) | 2017-06-13 | — | — | US | claimed |
| US-20170159044-A1 | COMPOSITIONS AND METHODS FOR SYNTHETIC GENE ASSEMBLY | Twist Bioscience Corporation | 2017-06-08 | — | — | US | claimed |
| US-20160264958-A1 | COMPOSITIONS AND METHODS FOR SYNTHETIC GENE ASSEMBLY | Twist Bioscience Corporation | 2016-09-15 | — | — | US | claimed |
| WO-2016126987-A1 | COMPOSITIONS AND METHODS FOR SYNTHETIC GENE ASSEMBLY | Twist Bioscience Corporation (US) | 2016-08-11 | — | — | WO | claimed |
| EP-2694524-B1 | 2'-O-AMINOOXYMETHYL NUCLEOSIDE DERIVATIVES FOR USE IN THE SYNTHESIS AND MODIFICATION OF NUCLEOSIDES, NUCLEOTIDES AND OLIGONUCLEOTIDES | US HEALTH (US) | 2016-05-18 | — | — | EP | claimed |
| US-9284343-B2 | 2′-O-aminooxymethyl nucleoside derivatives for use in the synthesis and modification of nucleosides, nucleotides and oligonucleotides | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2016-03-15 | — | — | US | claimed |
| US-7524942-B2 | Labeled nucleotide composition | AGILENT TECHNOLOGIES, INC. (US) | 2009-04-28 | — | — | US | claimed |
| WO-2009032057-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2009-03-12 | — | — | WO | claimed |
| US-20080124708-A1 | Labeled nucleotide composition | AGILENT TECHNOLOGIES, INC. | 2008-05-29 | — | — | US | claimed |
| US-20070212697-A1 | Labeled nucleotide composition | AGILENT TECHNOLOGIES, INC. | 2007-09-13 | — | — | US | claimed |
| US-5817799-A | 2'-Fluorofuranosyl derivatives and methods for preparing 2'-fluoropyrimidine and 2'-fluoropurine nucleosides | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-10-06 | — | — | US | claimed |
| EP-0540686-B1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | US COMMERCE (US) | 1995-08-30 | — | — | EP | claimed |
| EP-0570514-A4 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES INC (US) | 1994-08-17 | — | — | EP | claimed |
| EP-0570514-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1993-11-24 | — | — | EP | claimed |
| WO-1992013869-A1 | METHYLENE PHOSPHONATE NUCLEOSIDE ANALOGS AND OLIGONUCLEOTIDE ANALOGS MADE THEREFROM | GILEAD SCIENCES, INC. (US) | 1992-08-20 | — | — | WO | claimed |
| WO-1992001700-A1 | 2'-FLUOROFURANOSYL DERIVATIVES AND NOVEL METHOD OF PREPARING 2'-FLUOROPYRIMIDINE AND 2'-FLUOROPURINE NUCLEOSIDES | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, U.S. DEPARTMENT OF COMMERCE (US) | 1992-02-06 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080124708-A1 | Labeled nucleotide composition | RNGTT, RNMT, NOP2 | CYP3A4 3828/4885CYP1A2 3227/4885HIF1A 4231/4885 |
| US-20070212697-A1 | Labeled nucleotide composition | RNGTT, RNMT, NOP2 | CYP3A4 3828/4885CYP1A2 3227/4885HIF1A 4231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.